Thymosin Alpha-1 is a short, 28‑amino‑acid peptide produced by the thymus gland and available in a synthetic form called Thymalin. Dr. Jason Schuster highlights its potent immune‑modulating properties and why it deserves attention as a safe, versatile therapeutic tool.
Thymosin Alpha-1 Overview
Thymosin Alpha-1 is a 28‑amino‑acid peptide naturally secreted by the thymus and manufactured synthetically as Thymalin. It has been approved in more than 35 countries for hepatitis B and C and as a general immune enhancer, and in the United States it received orphan‑drug status for compassionate‑use trials. It is distinct from the longer peptide thymosin beta‑4 (43 amino acids).
- Synthetic form: Thymalin
- Approved in 35+ countries for hepatitis B/C
- U.S. orphan‑drug designation (1991‑2006)
- 28‑acid peptide vs. beta‑4’s 43 amino acids
How It Works
Dr. Schuster explains that Thymosin Alpha-1 boosts innate immunity by enhancing T‑cell function and natural killer cell activity. It modulates cytokine production, reduces inflammatory signaling, and directly interferes with viral replication, giving it broad antiviral and anti‑cancer potential.
- Enhances T‑cell maturation and activity
- Amplifies natural killer (NK) cell response
- Regulates cytokine balance to lower inflammation
- Displays direct antiviral effects in human and animal studies
Clinical Benefits
According to the video, Thymosin Alpha-1 has been studied for a range of conditions. It shows antiviral activity against hepatitis B/C, COVID‑19, and other chronic infections, and it exhibits anti‑cancer effects in hepatocellular carcinoma, malignant melanoma, and other tumors. Autoimmune disorders such as multiple sclerosis, Crohn’s disease, and vaccine‑induced autoimmunity also appear to improve with supplementation.
- Reduces mortality in moderate‑to‑severe COVID‑19 (2023 systematic review)
- Supports treatment of hepatitis B and C
- Anti‑cancer activity in liver cancer and melanoma
- Improves symptoms of multiple sclerosis, Crohn’s disease, and post‑vaccine autoimmunity
Typical Dosing Protocols
Dr. Schuster cites dosing regimens used by clinicians he trusts. One approach is 1.6–3.2 mg administered subcutaneously every two weeks. An alternative is 400–600 µg subcutaneously daily, often given daily for the first one to two weeks followed by maintenance every other week.
- 1.6–3.2 mg SC twice weekly
- 400–600 µg SC daily for 1–2 weeks, then bi‑weekly maintenance
- Dosing based on protocols from Dr. Edwin Lee
Safety Profile
The video references a 2024 meta‑analysis that found no severe adverse reactions or toxicity associated with Thymosin Alpha-1. A 2023 systematic review of eight COVID‑19 studies also reported zero intolerance. Dr. Schuster emphasizes that, to date, serious side effects have not been documented in the literature.
- Zero severe adverse reactions in 2024 meta‑analysis
- No intolerance reported in 2023 COVID‑19 systematic review
- Generally regarded as very safe across multiple studies
“Thymosin Alpha-1 is a potent antiviral and immune enhancer with essentially zero toxicity.”— Dr. Jason Schuster
Dr. Schuster's short takes on this topic — tap to play.
Go deeper than the summary
Dr. Schuster's accredited courses on supplementation, epigenetics, and peptide therapy — the full research, dosing, and video breakdowns.